HiFiBiO Therapeutics announced a clinical trial supply agreement with Novartis to evaluate tislelizumab, an anti-PD-1 immune checkpoint inhibitor, in combination with HiFiBiO's HFB200301, an investigational first-in-class monoclonal anti-TNFR2 agonist antibody for the potential treatment of advanced solid tumor indications preselected by HiFiBiO's proprietary Drug Intelligence Science (DIS) platform. HFB200301 is currently being evaluated as a single agent in the first-in-human dose escalation and expansion clinical trial (NCT05238883), with the intention of following up with a combination of HFB200301 and tislelizumab.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
89.46 CHF | +0.58% | +5.32% | +5.29% |
10:18am | Novartis: positive data for malaria treatment | CF |
09:26am | NOVARTIS AG : JP Morgan remains Neutral | ZD |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.29% | 199B | |
+27.92% | 672B | |
+27.19% | 570B | |
-4.59% | 360B | |
+16.38% | 321B | |
+9.39% | 300B | |
+7.58% | 217B | |
-8.92% | 204B | |
-8.58% | 149B | |
-4.99% | 147B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200301 in Combination with Tislelizumab in Patients with DIS™ Selected Advanced Solid Tumors